Two new teams in the Indian Premier League were sold earlier this week for astronomical sums of money. Is the valuation justified, and how long will it take for the teams to break even? Can the IPL have the long lifespan of international sporting leagues? Mohit Burman, owner of IPL team Punjab Kings and vice-chairman of Dabur India, as well as K Shriniwas Rao, sports journalist at The Times of India break down the numbers. Credits: CNBC-TV18, Star Sports, VR's Info, Tommy Official, Y.i Cricket TV, Munbai Indians, India Today

To make sense of the week’s hottest stories in business, economy, politics and markets, journalists from the Economic Times chat with reporters and industry leaders in this thrice-weekly (Tuesday, Thursday, Friday) podcast.

The Morning Brief

IPL Moneyball

The Unfinished Agenda

Reflecting on defining moments and tough tests

What more could Dr. Reddy’s have achieved?

Alignments and disagreements

Big picture view: are we nearing a major shift

Pharma shift to innovation, transformation lag

AI cuts drug timelines and reduces costs fast

From generics to innovation: is the pivot real

Consumer health boom: who will truly stand out

Indian investors undervalue pharma innovation

India: pharmacy of the world—what next?

India must close innovation gap with China now

Where should Dr. Reddy’s be a decade later

Credits

G.V. Prasad has spent over thirty years at the helm of Dr. Reddy's Laboratories — long enough to know where the opportunities were missed and where the potential and challenges lie. In a candid conversation with ET’s pharma editor Vikas Dandekar on Corner Office Conversation, the Co-Chairman and Managing Director pulls no punches: India is the generic pharmacy of the world, not the pharmacy of the world, and that distinction matters. He reflects on regulatory crises weathered, acquisitions never made, and an innovation pipeline that remained perpetually underfunded. On AI, he is deliberately unsentimental — helpful at the margins, not yet transformational. What he does believe in, firmly and urgently, is Dr. Reddy's next act: a decisive pivot from incremental generics to innovation-led growth, with a hard target and a ticking clock.

You can follow Vikas Dandekar on his social media: X and Linkedin and read her Newspaper Articles.

Listen to Corner Office Conversation: Corner Office Conversation with Sridhar Vembu, CEO, of Zoho Corporation, Corner Office Conversation with Gunjan Soni, Country Managing Director, Youtube India, Corner Office Conversation with Elizabeth Reid, Head of Search, Google, Corner Office Conversation with Rajan Anandan, Managing Director, Peak XV & Surge and much more.

Catch the latest episode of “Corner Office Conversation” on: Spotify, Amazon Music, Apple Podcasts,and wherever you get your podcasts from.

G.V. Prasad has spent over thirty years at the helm of Dr. Reddy's Laboratories &mdash; long enough to know where the opportunities were missed and where the potential and challenges lie. In a candid conversation with ET&rsquo;s pharma editor Vikas Dandekar on Corner Office Conversation, the Co-Chairman and Managing Director pulls no punches: India is the generic pharmacy of the world, not the pharmacy of the world, and that distinction matters. He reflects on regulatory crises weathered, acquisitions never made, and an innovation pipeline that remained perpetually underfunded. On AI, he is deliberately unsentimental &mdash; helpful at the margins, not yet transformational. What he does believe in, firmly and urgently, is Dr. Reddy's next act: a decisive pivot from incremental generics to innovation-led growth, with a hard target and a ticking clock. You can follow Vikas Dandekar on his social media:<a href="https://twitter.com/VikasReports"> X</a> and<a href="https://www.linkedin.com/in/vikas-dandekar-2a0a619"> Linkedin</a> and read her<a href="https://economictimes.indiatimes.com/etreporter/author-vikas-dandekar-479242213.cms?from=mdr"> Newspaper Articles</a>. Listen to Corner Office Conversation:<a href="https://podcasts.apple.com/in/podcast/corner-office-conversation-with-sridhar-vembu-ceo-of/id1827451035?i=1000731722117"> Corner Office Conversation with Sridhar Vembu, CEO, of Zoho Corporation</a>,<a href="https://podcasts.apple.com/in/podcast/corner-office-conversation/id1827451035?i=1000731513423"> Corner Office Conversation with Gunjan Soni, Country Managing Director, Youtube India</a>,<a href="https://podcasts.apple.com/in/podcast/corner-office-conversation/id1827451035?i=1000728953575"> Corner Office Conversation with Elizabeth Reid, Head of Search, Google</a>,<a href="https://podcasts.apple.com/in/podcast/corner-office-conversation/id1827451035?i=1000748828081"> Corner Office Conversation with Rajan Anandan, Managing Director, Peak XV &amp; Surge</a> and<a href="https://podcasts.apple.com/in/podcast/corner-office-conversation/id1827451035"> much more</a>.
Catch the latest episode of &ldquo;Corner Office Conversation&rdquo; on:<a href="https://open.spotify.com/show/4fq4hKHPZO3MVDNhtOQ5OU?si=99e033dfb01a44c7"> Spotify</a>,<a href="https://music.amazon.com/podcasts/1f0c9fc5-f702-4a84-bd7d-4f010bea72a5/corner-office-conversation"> Amazon Music</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> Apple Podcasts</a>,and wherever you get your podcasts from.

Corner Office Conversation with  G.V. Prasad, Co-Chairman and Managing Director Dr Reddy’s Laboratories Ltd

Work Rewritten by AI

LinkedIn as AI Engine

AI Skills Across Jobs

Redesigning Roles and Mentorship

Skills Frameworks and Verified Skills

Closing the Skills Gap

AI Tools and Doer to Director

Bias Transparency and Control

Final Takeaways 

A billion professionals. Eighteen years of data. And a skills gap that's widening as AI tools multiply. Mohak Shroff has watched LinkedIn evolve from a professional network into what he calls, at its core, an AI matching engine. That vantage point gives Shroff, SVP Engineering at Linkedin, a clear read on what's actually happening inside organisations right now. Not the boardroom narrative, but the messy reality of workers who don't know which skills to build, recruiters who can't find candidates despite better tooling, and companies confusing access to AI with genuine AI readiness.

Listen in

A billion professionals. Eighteen years of data. And a skills gap that's widening as AI tools multiply. Mohak Shroff has watched LinkedIn evolve from a professional network into what he calls, at its core, an AI matching engine. That vantage point gives Shroff, SVP Engineering at Linkedin, a clear read on what's actually happening inside organisations right now. Not the boardroom narrative, but the messy reality of workers who don't know which skills to build, recruiters who can't find candidates despite better tooling, and companies confusing access to AI with genuine AI readiness.
Listen in

From Doer to Director: The LinkedIn Playbook for the AI Age

Generic AI flood: excited chaos, or just noise

GLP-1s: The New Standard for Metabolic Care?

India's GLP-1 Race: Rules, Reach & Reality

Post-March 21st: Who Wins the GLP-1 Market?

Stand Out or Fade Out in the GLP-1 Race

Big or Small: Who Wins the GLP-1 Script?

Will Patients Stick With GLP-1s This Time?

GLP-1 Buzz: Awareness or a Recipe for Misuse

GLP-1 Safeguards: Are Global Checks Enough?

Semaglutide Goes Global: Even Africa Is Next?

Pills or Shots: How Will Semaglutide Be Taken?

Will Small Molecules Challenge the GLP-1 Era?

Dos & Don'ts: For Companies and Patients Both

Conclusion

India's semaglutide moment has arrived. As Novo Nordisk's patent expires on March 20th, over fifty generic brands are poised to flood the market potentially slashing monthly costs from ₹10,000 to ₹3,500. But this is no ordinary generic wave. Semaglutide is a complex peptide, cold chains are unforgiving, and patient adherence remains fragile. Host and ET’s pharma editor Vikas Dandekar talks to Sheetal Sapale, Vice President, Pharmarack, Dr. Rajiv Kovil, Diabetologist, Saurabh Agarwal, Director at HAB Pharmaceuticals and Research, Dr. Saurabh Jain, Vice President - Global Delivery Centers, Indegene and Vijay Charlu, President of Domestic Business, Corona Remedies to dissect who survives the shakeout, what it means for a slew of weight loss drugs in India, whether it will revolutionise metabolic treatment and whether India is truly ready for its statin moment.

You can follow Vikas Dandekar on his social media: X and Linkedin and read her Newspaper Articles.

Check out other interesting episodes like: How Will a Volatile ₹ Impact You in 2026?, How Quick Commerce is Triggering a Health Crisis for Gen Z, India’s Labour Law Reboot, Viral to Valuation: Building Women’s Cricket as a Brand and much more.

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

India's semaglutide moment has arrived. As Novo Nordisk's patent expires on March 20th, over fifty generic brands are poised to flood the market potentially slashing monthly costs from ₹10,000 to ₹3,500. But this is no ordinary generic wave. Semaglutide is a complex peptide, cold chains are unforgiving, and patient adherence remains fragile. Host and ET&rsquo;s pharma editor Vikas Dandekar talks to Sheetal Sapale, Vice President, Pharmarack, Dr. Rajiv Kovil, Diabetologist, Saurabh Agarwal, Director at HAB Pharmaceuticals and Research, Dr. Saurabh Jain, Vice President - Global Delivery Centers, Indegene and Vijay Charlu, President of Domestic Business, Corona Remedies to dissect who survives the shakeout, what it means for a slew of weight loss drugs in India, whether it will revolutionise metabolic treatment and whether India is truly ready for its statin moment. You can follow Vikas Dandekar on his social media: <a href="https://twitter.com/VikasReports">X</a> and <a href="https://www.linkedin.com/in/vikas-dandekar-2a0a619">Linkedin</a> and read her <a href="https://economictimes.indiatimes.com/etreporter/author-vikas-dandekar-479242213.cms?from=mdr">Newspaper Articles</a>. Check out other interesting episodes like: <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000742733036">How Will a Volatile ₹ Impact You in 2026?</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000740924439">How Quick Commerce is Triggering a Health Crisis for Gen Z</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738734300">India&rsquo;s Labour Law Reboot</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738205536">Viral to Valuation: Building Women&rsquo;s Cricket as a Brand</a> and <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777">much more</a>. Catch the latest episode of &lsquo;The Morning Brief&rsquo; on <a href="https://economictimes.indiatimes.com/podcast?from=mdr">The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777">Apple Podcasts</a>, <a href="https://www.jiosaavn.com/shows/the-morning-brief/1/GNPiFQD2xpY_">JioSaavn</a>, <a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief">Amazon Music</a> and <a href="https://www.youtube.com/@theetpodcasts">Youtube</a>.

Semaglutide Goes Generic: Big Pharma’s Moat Breaks

IPL Moneyball

The Morning Brief

In 1 playlist(s)

The Morning Brief

Social links

Follow podcast

Recent clips